EP
ITCI

Edgestream Partners’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Edgestream Partners’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,636
Closed -$304K – 1124
2024
Q4 		$304K Sell
3,636
-50,993
-93% -$4.19M 0.01% 756
2024
Q3 		$4M Buy
+54,629
New +$4.11M 0.18% 187
2024
Q2 		– Sell
-18,137
Closed -$1.26M – 1078
2024
Q1 		$1.26M Buy
18,137
+4,707
+35% +$324K 0.06% 447
2023
Q4 		$962K Sell
13,430
-30,656
-70% -$1.76M 0.07% 450
2023
Q3 		$2.3M Buy
44,086
+19,980
+83% +$1.16M 0.18% 158
2023
Q2 		$1.53M Buy
+24,106
New +$1.5M 0.14% 257

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Edgestream Partners's ITCI Position: Q1 2025 in Review

Edgestream Partners sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 3,636 shares — an estimated $304K sold.

Edgestream Partners first reported a position in ITCI in Q2 2023 and held it in 6 quarters. The position peaked at $4M in Q3 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Edgestream Partners reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • Edgestream Partners sold 3,636 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $304K.
  • Edgestream Partners first reported a position in Intra-Cellular Therapies Inc. in Q2 2023 and held it in 6 quarters.
  • Edgestream Partners's Intra-Cellular Therapies Inc. position peaked at $4M in Q3 2024.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Edgestream Partners's 13F filing for Q1 2025, filed 2 May 2025.